NewLink Genetics is a clinical-stage immuno-oncology company focused on discovering and developing immunotherapeutic products for the treatment of patients with cancer. Co.'s small-molecule product candidates in clinical development target the indoleamine-2, 3-dioxygenase (IDO) pathway. Co.'s product candidates include: indoximod and NLG802 (a prodrug of indoximod), which are IDO pathway inhibitors with mechanisms of action that center around breaking the immune system's tolerance to cancer; and NLG207, which is a nanoparticle-drug conjugate consisting of a cyclodextrin-based polymer backbone linked to camptothecin, a topoisomerase 1 inhibitor of the topoisomerase-1 inhibitor, camptothecin. We show 39 historical shares outstanding datapoints in our NLNK shares outstanding history coverage, used to compute NLNK market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing NLNK market cap history over the course of time is important for investors
interested in comparing NLNK's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of NLNK versus a peer is one thing; comparing
NLNK market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like NLNK can fluctuate over the course of history.
With this page we aim to empower investors researching NLNK by allowing them to research the NLNK market cap history. |
Free NLNK Email Alerts:
Video: The Importance of Market Cap
